Pavlou S N, Wakefield G B, Island D P, Hoffman P G, LePage M E, Chan R L, Nerenberg C A, Kovacs W J
J Clin Endocrinol Metab. 1987 May;64(5):931-6. doi: 10.1210/jcem-64-5-931.
LHRH antagonists compete with endogenous LHRH for binding to receptors on pituitary gonadotrophs and thereby inhibit gonadal function by suppressing gonadotropin secretion. We studied the effects of a recently developed LHRH antagonist on the pituitary-gonadal axis in man. The antagonist Detirelix [( N-Ac-D-Nal(2)1, D-pCl-Phe2,D-Trp3, D-hArg(Et2)6, D-Ala10]LHRH) was given as a single sc injection to nine normal men at three dose levels (5, 10, and 20 mg) at intervals of at least 7 days. Serum FSH, LH, and testosterone levels were measured before treatment, at frequent intervals for 48 h, and 72, 96, and 168 h after administration of the antagonist. Mean serum FSH levels decreased (P less than 0.001) from 6.9 +/- 0.5 (+/- SEM) mIU/mL to nadirs of 4.4 +/- 1.1, 3.6 +/- 0.9, and 4.1 +/- 0.9 after the 5-, 10-, and 20-mg doses, respectively. Serum LH levels decreased (P less than 0.001) from 6.2 +/- 0.3 mIU/mL to nadirs of 3.3 +/- 0.4, 2.8 +/- 0.3, and 2.7 +/- 0.3 after all three doses. Serum testosterone levels decreased (P less than 0.001) in a dose-dependent fashion from 5.1 +/- 0.2 ng/mL to nadirs of 1.3 +/- 0.3, 0.9 +/- 0.3, and 0.6 +/- 0.1 after the same doses. After the initial testosterone decrease, however, escape occurred 12-28 h after the lower doses. The area under the response curve, describing hormone concentrations as a function of time during the study, diminished by 23 +/- 2%, 36 +/- 4%, and 36 +/- 3% for FSH, by 14 +/- 6%, 30% +/- 6%, and 34 +/- 5% for LH, and by 41 +/- 5%, 58 +/- 6%, and 68 +/- 4% for testosterone with the same doses, respectively. The apparent plasma disappearance half-life of Detirelix by RIA was at least 41 h after all three doses. Detirelix elicited only a minor local reaction; no systemic side-effects were observed within the dose range used. These results indicate that this LHRH antagonist is a safe, highly potent inhibitor of the human pituitary-gonadal axis with an exceptionally long duration of action.
促性腺激素释放激素(LHRH)拮抗剂与内源性LHRH竞争,以结合垂体促性腺细胞上的受体,从而通过抑制促性腺激素分泌来抑制性腺功能。我们研究了一种最近开发的LHRH拮抗剂对人体垂体 - 性腺轴的影响。拮抗剂地瑞瑞克[(N - 乙酰 - D - 萘丙氨酸(2)1,D - 对氯苯丙氨酸2,D - 色氨酸3,D - 高精氨酸(乙基)6,D - 丙氨酸10)LHRH]以单次皮下注射的方式给予9名正常男性,剂量分为三个水平(5、10和20毫克),间隔至少7天。在治疗前、给药后48小时内频繁测量血清促卵泡生成素(FSH)、促黄体生成素(LH)和睾酮水平,以及给药后72、96和168小时的水平。平均血清FSH水平在给予5毫克、10毫克和20毫克剂量后分别从6.9±0.5(±标准误)毫国际单位/毫升降至最低点4.4±1.1、3.6±0.9和4.1±0.9(P<0.001)。血清LH水平在所有三个剂量后均从6.2±0.3毫国际单位/毫升降至最低点3.3±0.4、2.8±0.3和;2.7±0.3(P<0.001)。血清睾酮水平以剂量依赖性方式从5.1±0.2纳克/毫升降至相同剂量后的最低点1.3±;0.3、0.9±0.3和0.6±0.1(P<0.001)。然而,在较低剂量给药后12 - 28小时出现了睾酮水平的回升。在研究期间,描述激素浓度随时间变化的反应曲线下面积,FSH分别减少了23±2%、36±4%和36±3%,LH分别减少了14±6%、30±6%和34±5%,睾酮分别减少了41±5%、58±6%和68±4%。通过放射免疫分析(RIA)测定,所有三个剂量后地瑞瑞克在血浆中的表观消失半衰期至少为41小时。地瑞瑞克仅引起轻微的局部反应;在所使用的剂量范围内未观察到全身副作用。这些结果表明,这种LHRH拮抗剂是一种安全、高效的人体垂体 - 性腺轴抑制剂,作用持续时间极长。